OTLK - Outlook Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0400
-0.0300 (-1.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0700
Open2.0700
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range1.9700 - 2.1600
52 Week Range0.2050 - 8.8000
Volume630,711
Avg. Volume4,913,307
Market Cap53.144M
Beta (3Y Monthly)-0.45
PE Ratio (TTM)N/A
EPS (TTM)-4.9550
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • Hottest Wall Street Stories: What's Up, What's Down
    Zacks17 days ago

    Hottest Wall Street Stories: What's Up, What's Down

    Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.

  • GlobeNewswire17 days ago

    Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retinal diseases, today announced that it has signed a master services agreement with FUJIFILM Diosynth Biotechnologies (FDB) for the production of ONS-5010. Under the terms of this agreement, FDB will provide global manufacturing of ONS-5010 to Outlook in support of the commercialization strategy for the drug.

  • Benzinga27 days ago

    A Look At Benzinga Pro's Most-Searched Tickers For May 24

    Tesla Inc  (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...

  • MarketWatchlast month

    Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days

    Shares of Outlook Therapeutics Inc. rocketed on heavy volume in premarket trade Monday, putting them on track to nearly triple in three days, in the wake of the biotechnology company's upbeat update on a drug trial and bullish analyst report. The stock 27% ahead of the open on premarket leading volume of 4.2 million shares, after running up 37% on volume of 76.7 million shares on Friday and after soaring 68% on 51.7 million shares on Thursday. On Wednesday, the stock had closed at 91 cents. On Thursday, Oppenheimer analyst Leland Gershell started coverage of Outlook with an outperform rating and $12 stock price, and the company said two phase 3 studies remain on track with its plan to submit its monoclonal antibody therapeutic product for regulatory approval in 2020. The stock had still lost 78.1% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has lost 6.6% and the S&P 500 has gained 4.4%.

  • Benzingalast month

    Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know

    Outlook Therapeutics — previously known as Oncobiologics — announced board approval for a 1-for-8 reverse stock split that took effect March 18. This essentially reduced the number of outstanding shares from 94.1 million to 11.8 million. After closing at 91 cents May 15, Outlook shares gap opened Thursday and traded in a $1.15-$1.77 range before ending the session over 68-percent higher at $1.53.

  • MarketWatchlast month

    Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days

    Shares of Outlook Therapeutics Inc. rocketed 38% in very active morning trade Friday, putting them on track to more than double in two days. Volume ballooned to 17.6 million shares, enough to make the stock the most actively traded on the Nasdaq exchange. The biotechnology company's stock had run up 68% on Thursday on trading volume of 51.7 million shares, after closing Wednesday at a record low of 91 cents, after Oppenheimer analyst Leland Gershell started coverage with an outperform rating and $12 stock price target. Outlook is investigating a formulation of a treatment of wet age-related macular degeneration. Outlook's stock was still down 47% year to date, while the iShares Nasdaq Biotechnology ETF has gained 7.9% and the S&P 500 has advanced 14%.

  • MarketWatchlast month

    Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer

    Oppenheimer initiated coverage of Outlook Therapeutics Inc's stock on Thursday at a price target of $12, while giving it an outperform rating. It's a big show of confidence for the tiny biotech, whose shares shot up 26% on Thursday morning and are now trading at around $1. Outlook is investigating a formulation of bevacizumab it calls ONS-5010, meant to treat wet age-related macular degeneration. The main wet AMD drugs right now are Genentech's Lucentis, Regeneron Pharmaceuticals Inc's Eylea and Avastin, also by Genentech. Avastin, an oncology drug used off label to treat wet AMD, is popular among providers and payers because it's cheaper than Lucentis and Eylea. However, risk of contamination has been a concern for the FDA, and Oppenheimer thinks ONS-5010 could one day end up taking over Avastin's large share of the AMD space. Shares of the company have fallen 71% in the year to date, while the S&P 500 has gained 14.4%.

  • GlobeNewswirelast month

    Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019

    CRANBURY, N.J., May 15, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal quarter.

  • GlobeNewswire2 months ago

    Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that Jennifer M. Kissner, Ph.D. has joined the Company as Senior Vice President, Clinical Development.

  • GlobeNewswire2 months ago

    Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the pricing of an underwritten public offering of 10,340,000 shares of its common stock, 15-month warrants to purchase up to an aggregate of 10,340,000 shares of common stock, and 5-year warrants to purchase up to an aggregate of 10,340,000 shares of common stock. BioLexis Pte. Ltd. (BioLexis), the Company’s strategic business partner and largest stockholder, led this financing with a $10 million investment. The shares of common stock and accompanying warrants are being sold at a combined public offering price of $2.75.

  • GlobeNewswire3 months ago

    Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the U.S. Food and Drug Administration (FDA) acceptance and activation of the Investigational New Drug (IND) application for the Company’s lead product candidate, ONS-5010, an innovative monoclonal antibody (mAb) therapeutic product candidate being developed for wet age related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).  The Company is now able to begin enrolling patients with wet AMD in the U.S. portion of its ONS-5010-002 Phase 3 clinical trial.

  • GlobeNewswire3 months ago

    Outlook Therapeutics Announces Reverse Stock Split

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 reverse stock split of the Company’s common stock, which became effective this morning immediately upon the filing by the Company of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware. Beginning on March 18, 2019, the Company’s common stock will trade on the Nasdaq Capital Market on a reverse stock split-adjusted basis under the new CUSIP number 69012T206.

  • GlobeNewswire4 months ago

    Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements

    CRANBURY, N.J., March 05, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today that the Company received formal notice from The Nasdaq Stock Market.

  • GlobeNewswire4 months ago

    Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ONS-5010. ONS-5010 is an innovative monoclonal antibody (mAb) therapeutic product candidate being developed for wet age related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Once effective, the IND will allow the Company to begin enrolling patients in the U.S. portion of its ONS-5010-002 Phase 3 clinical trial in patients with wet AMD.

  • GlobeNewswire4 months ago

    Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019

    CRANBURY, N.J., Feb. 14, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal quarter.

  • ACCESSWIRE4 months ago

    Healthcare Investment Opportunities You Can't Miss

    HENDERSON, NV / ACCESSWIRE / February 13, 2019 / When looking for great growth opportunities to invest in, look no further than the healthcare sector. Healthcare stocks have consistently produced big winners ...

  • GlobeNewswire5 months ago

    Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement

    CRANBURY, N.J., Feb. 01, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million.

  • GlobeNewswire5 months ago

    Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants

    Outlook Therapeutics, Inc. (Nasdaq: OTLK, OTLKW) (the “Company”) today announced that its publicly traded Series A warrants (OTLKW) have been amended to lower the exercise price to $1.50 per share and further extend the maturity until 5:00 p.m. New York City time on February 18, 2022. The Series A warrants were issued as part of the units in its May 2016 initial public offering and in a concurrent private placement and were exercisable for shares of its common stock at an initial exercise price of $6.60 per share. The Series A warrants, as previously extended, would have expired at 5:00 p.m. New York City time on the earlier to occur of (a) the date that was twenty (20) business days after the date on which the closing sales price of the common stock was greater than or equal to $7.25 per share and (b) February 18, 2019.

  • GlobeNewswire6 months ago

    Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business partner and largest investor, receiving $4.0 million of cash proceeds in exchange for the issuance of 4,288,624 shares of common stock at $0.9327 per share.  The Company has received $16.0 million to date from the sale of its common stock to BioLexis under this private placement, which was previously announced on November 6, 2018.  The remaining $4.0 million will be funded on February 1, 2019, subject to achieving certain funding milestones as set forth in the purchase agreement. The Company intends to use the net proceeds from the private placement primarily for clinical trials for its lead product candidate, ONS-5010, and for working capital and general corporate purposes, including agreed repayments on its senior secured notes.

  • GlobeNewswire6 months ago

    Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018

    CRANBURY, N.J., Dec. 18, 2018 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its fiscal year ended.